
    
      STANDARD CARE: All participants receive cisplatin intravenously (IV) over 30-60 minutes on
      days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions for
      5 days a week, for up to 8 weeks in the absence of disease progression or unacceptable
      toxicity. Four (4) to 8 weeks after finishing standard chemotherapy and radiation,
      participants are randomized to 1 of 2 arms.

      RANDOMIZED ARMS:

      Arm I: Patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1.
      Courses repeat every 21 days for up to 4 courses in the absence of disease progression or
      unacceptable toxicity. Participants are followed at 3, 6, 9, 12, 18 and 24 months for
      recurrence or progression.

      Arm II: Participants undergo active monitoring at 3, 6, 9, 12, 18 and 24 months for
      recurrence or progression.
    
  